Efficacy of fluoxetine and paroxetine on depression-anxiety, quality of life, disability and metabolic control in diabetic patients with major depressive disorder: A single-blind, comparative study;Major depresif bozukluǧu olan diabetes mellituslu hastalarda fluoksetin ve paroksetinin depresyon-anksiyete, yaşam kalitesi, yeti yitimi ve metabolik kontrol üzerine etkisi: Tek-kör, karşilaştirmali bir çalişma

Klinik Psikofarmakoloji Bulteni

Volumn 11, Issue 1, 2001, Pages 1-10

  Gülseren, Leyla ^a,c   Gülseren, Şeref ^a   Hekimsoy, Zeliha ^a   Bodur, Zeynep ^b   Kültür, Savaş ^a  

^a Izmir Ataturk Training and Research Hospital   (Turkey)

^b Bornova Acil Yardim ve Trafik Hastanesi   (Turkey)

^c Bornova Acil Yardim ve Trafik Hastanesi ^*  (Turkey)

Author keywords

Anxiety; Depression; Diabetes mellitus; Disability; Quality of life; SSRI

Indexed keywords

EID: 25544476033     PISSN: 10177833     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Lustman PJ, Griffith LS, Clouse RE, Cryer PE. Psychiatric ilness in diabetes mellitus. Relationship to symptoms and glucose control. J Nerv Ment Dis 1986;174:736-42
2. Popkin MK, Callies AL, Lentz RD, Colon EA, Sutherland DE. Prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type 1 diabetes mellitus. Arch Gen Psychiatry 1988;45:64-68
3. Eiber R, Berlin I, Grimaldi A, Bisserbe JC. Insulin-dependent diabetes and psychiatric pathology: general clinical and epidemiologic review. Encephale 1997;23:351-57
4. Geffken GR, Ward HE, Staab JP, Carmichael SLK, Evans DL. Psychiatric morbidity in endocrine disorders. CB Nemeroff (ed), The Psychiatric Clinics of North America 1998;21:473-89
5. Özkan S, Turgay M Tip I-II diabetik hastalarda psikiyatrik morbidite ve hastalikla baş etme guçlükleri. In: Özkan S (ed) Konsültasyon-Liyezon Psikiyatrisi, I. baski, İstanbul, 1994:398-407
6. Çolak R, Yabanoǧlu İ, Baştürk M, Bayram F, Sofuoǧlu S, Keleştimur F. Diabetes mellituslu hastalarin psikiyatrik deǧerlendirilmesi. XXXV. Ulusal Diyabet Kongresi ve Uluslararasi Obesite Sempozyumu Bildiri Kitabi, 1999:42
7. Warnock JK, Mutzig EM. Diabetes mellitus and major depression: considerations for treatment of Native Americans. J Okla State Med Assoc 1998;91:488-93
8. Leedom L, Meehan WP, Procci W, Zeidler A. Symptoms of depression in patients with type II diabetes mellitus. Psychosomatics 1991;32:280-86
9. Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, Carney RM, McGill JB. Effects of nortriptyline on depression and glycemic control in diabetes:results of a double-blind, placebo-controlled trial. Psychosom Med 1997;59:241-50
10. Lustman PJ, Griffith LS, Freedland KE, Clouse RE The course of major depression in diabetes. Gen Hosp Psychiatry 1997;19:138-43
11. Okamura F, Tashiro A, Utsumi A, Imai T, Suchi T, Hongo M Insulin resistance in patients with depression and its changes in the clinical course of depression. Intern Med 1999;38:257-60
12. Goodnick PJ, Henry JH, Buki VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 1995;56:128-36
13. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, Dubner R. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-96
14. Sindrup SH, Ejlertsen B, Froland A, Sindrup EH, Brosen K, Gram LF. Imipramine treatment in diabetic neuropathy:relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989;37:151-53
15. Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 1996;8:459-76
16. Joss JD. Tricyclic antidepressant use in diabetic neuropathy. Ann Pharmacother 1999;33:996-1000
17. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-44
18. Holliday SM, Plosker GL. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Drugs 1993;3:278-99
19. Goodnick PJ, Jimenez I, Kumar A. Sertraline in diabetic neuropathy: preliminary results. Ann Clin Psychiatry 1997;9:255-57
20. Weinberger M, Kirkman MS, Samsa GP, Shortliffe EA, Landsman PB, Cowper PA, Simel DL, Feussner JR. A nurse-coordinated intervention for primary care patients with non-insulin-deperndent diabetes mellitus:impact on glycemic control and health-related quality of life. J Gen Intern Med 1995;10:59-66
21. Lee PP, Whitcup SM, Hays RD, Spritzer K, Javitt J. The relationship between visual acuity and functioning and wellbeing among diabetics. Qual Life Res 1995;4:319-23
22. Tilly KF, Belton AB, McLachlan JF. Continuous monitoring of health status outcomes:experience with a diabetes education program. Diabetes Educ 1995;21:413-19
23. Piehlmeier W, Bullinger M, Kirschberger I, Land W, Landgraf R. Evaluation of the quality of life of patients with insulin-dependent diabetes mellitus before and after organ transplantation with the SF-36 health survey. Eur J Surg 1996;162:933-40
24. Wikblad K, Smide B, Bergstrom A, Kessi J, Mugusi F. Outcome of clinical foot examination in relation to self-perceived health and glycaemic control in a grup of urban Tanzanian diabetic patients. Diabetes Res Clin Pract 1997;37:185-92
25. Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A. Domperidone in the management of symptoms of diabetic gastroparesis:efficacy, tolerability, and quality- of-life outcomes in a multicenter controlled trial. Clin Ther 1998;20:438-53
26. Wu SY, Sainfort F, Tomar RH, Tollios JL, Fryback DG, Klein R, Klein BE. Development and application of a model to estimate the impact of type 1 diabetes on health-related quality of life. Diabetes Care 1998;21:725-31
27. DeFronzo RA. Goals of Diabetes Management. Current Management of Diabetes Mellitus, cilt 1, DeFronzo (ed), Philadelphia, Mosby A Times Mirror Company, 1998; pp.5-7
28. Skyler JS. Monitoring of Type 1 Diabetes Mellitus. Current Management of Diabetes Mellitus, cilt 1, DeFronzo RA (ed), Philadelphia, Mosby A Times Mirror Company, 1998; pp. 50-54
29. American Psychiatric Association (1994) Mental Bozukluklar Tamsal ve Sayimsal Elkitabi, dördüncü baski (DSM-1V) (Çev. Ed: E. Köroǧlu) Hekimler Yayin Birliǧi, Ankara, 1995
30. Zigmond AS, Snaith PR. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-70
31. Aydemir Ö, Güvenir T, Küey L, Kültür S. Hastane Anksiyete ve Depresyon Ölçeǧi Türkçe Formu'nun Geçerlilik ve Güvenilirliǧi. Türk Psikiyatri Dergisi 1997;8:280-7
32. Williams BW. A structured interview guide for Hamilton Depression Rating Scale. Arcs Gen Psychiatr 1978;45:742-47
33. Akdemir A, Örsel S, Daǧ İ, Türkçapar MH, Ïşcan N, Özbay H. Hamilton depresyon derecelendirme ölçeǧi (HDDÖ)'nin geçerliǧi, güvenirliǧi ve klinikte kullammi. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996;4:251-59
34. Aydemir Ö, Köroǧlu E. Psikiyatride Kullamlan Klinik Ölçekler. Hekimler Yayin Birliǧi, Ankara, 2000
35. Yazici MK, Demir B, Tanriverdi N, Karaaǧaoǧlu E, Yolaç P. Hamilton Anksiyete Deǧerlendirme Ölçeǧ i, deǧerlendiriciler arasi güvenirlik ve geçerlik çalişmasi. Türk Psikiyatri Dergisi 1998;9:114-17
36. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
37. Koçyiǧit H, Aydemir Ö, Ölmez N, Memiş A. SF-36'nin Türkçe için guvenilirliǧi ve geçerliliǧi. Ege Fizik Tedavi ve Rehabilitasyon Dergisi 1999
38. Aydemir Ö. Konsültasyon-liyezon psikiyatrisinde yaşam kalitesi ölçümü: Kisa Form-36 (SF-36). Psikiyatri, Psikoloji, Psikofarmakoloji Dergisi 1999;7 (Ek. 2) 14-22
39. Stewart AL, Hays RD, Ware JEJ. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988;26:724-35
40. Kaplan İ. Yankirsal bir saǧlik ocaǧina bašvuran hastalarda ruhsal bozukluklarin yetiyitimi ile ilişkisi. Türk Psikiyatri Dergisi 1995;6:169-79
41. Goodnick PJ, Kumar A, Henry JH, Buki VM, Goldberg RB. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997;33:261-64
42. Winocour PH, Main CJ, Medlicott G, Anderson DC. A psychometric evaluation of adult patients with type 1 (insulin-dependent) diabetes mellitus. Prevalence of psychological dysfunction and relationship to demographic variables, metabolic control and complications. Diabetes Res 1990;14:171-76
43. Kuloǧlu M, Karaoǧlu A, Atmaca M, Özkan Y, Tezcan AE. Tip II Diabetik Hastalarda Psikiyatrik Belirtiler ve Kan Şekeri Kontrolü. Düşünen Adam 2000;13:19-23
44. Lustman PJ, Griffith LS, Freedland KE. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;15:613-21
45. Gray DS, Fujioka K, Devine W, Bray GA. A randomized double-blind trial of fluoxetine in obese diabetics. Int J Obes relat Metab Disord 1992;16 (suppl 4):67-72
46. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994;11:105-10
47. Connoly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med 1995;12:416-18
48. Breum L, Bjerre LJ, Bak JF, Jacobsen S, Astrup A. Longterm effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance:influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 1995;44:1570-76
49. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 1996;4:391-96
50. Potter van Loon BJ, Radder JK, Frolich M, Krans HM, Zwinderman AH, Meinders AE. Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992;16 (suppl. 4):55-61
51. Kohen D, Burgens AP, Catalan J, Lant A. The role of anxiety and depression in quality of life and symptom reporting in people with diabetes mellitus. Qual Life Res 1998;7:197-204